The insider sales are too small relative to market cap to signal a fundamental concern. Monitor the next 10-Q for any change in the $2.0B buyback execution pace and for further insider activity that exceeds the 0.1% of market cap threshold.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $591.17entry
- T+1 · 17h ago −0.56%α +1.35% · $587.88
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three insiders at United Therapeutics sold a total of $1.67M in open-market sales within a week of the company reporting Q3 revenue above consensus but EPS below consensus due to a $130M in-process R&D charge. CEO Martine Rothblatt's sales were under a 10b5-1 plan, while director Christopher Patrusky's sale was not. The total value is 0.007% of the $25.1B market cap, well below the 0.1% threshold for materiality.
Key Financial Metrics
Key Facts
- Three insiders sold a total of $1.67M in open-market sales over a 7-day window ending Nov 10, 2026.
- CEO Martine Rothblatt sold $288K under a 10b5-1 plan; EVP & General Counsel Paul Mahon sold $683K under a 10b5-1 plan; Director Christopher Patrusky sold $702K without a 10b5-1 plan.
- Total sales represent approximately 0.007% of the $25.1B market cap, which is trivial.
- Q3 2026 revenue of $832.5M beat the $781.1M consensus, but GAAP diluted EPS of $5.71 missed the $6.04 consensus due to a $130M in-process R&D charge from the Thymmune acquisition.
- The company announced a new $2.0B share repurchase authorization on Nov 4, 2026.
Financial Impact
Total insider sales of $1.67M, or 0.007% of market cap, are immaterial.
Risk Factors
- Insider sales are routine and immaterial in size; no elevated risk indicated.
- CEO and EVP sales were under 10b5-1 plans, suggesting pre-planned liquidity, not a reaction to recent results.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-UTHR-1794519529202 |
Track record
123 reports on UTHR
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry $587.88 Now $587.88 +0.00% settles Nov 24
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Viewing Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers